|
1
|
Chen D and Dou QP: Tea polyphenols and
their roles in cancer prevention and chemotherapy. Int J Mol Sci.
9:1196–1206. 2008. View Article : Google Scholar
|
|
2
|
Berdowska I, Zieliński B, Fecka I,
Kulbacka J, Saczko J and Gamian A: Cytotoxic impact of phenolics
from Lamiaceae species on human breast cancer cells. Food Chem.
141:1313–1321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woodman OL and Chan EC: Vascular and
anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol
Physiol. 31:786–790. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russo P, Del Bufalo A and Cesario A:
Flavonoids acting on DNA topoisomerases: Recent advances and future
perspectives in cancer therapy. Curr Med Chem. 19:5287–5293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guerra-Araiza C, Álvarez-Mejía AL,
Sánchez-Torres S, Farfan-García E, Mondragón-Lozano R,
Pinto-Almazán R and Salgado-Ceballos H: Effect of natural exogenous
antioxidants on aging and on neurodegenerative diseases. Free Radic
Res. 47:451–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kritas SK, Saggini A, Varvara G, Murmura
G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas
S, et al: Luteolin inhibits mast cell-mediated allergic
inflammation. J Biol Regul Homeost Agents. 27:955–959. 2013.
|
|
7
|
Sak K: Cytotoxicity of dietary flavonoids
on different human cancer types. Pharmacogn Rev. 8:122–146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaul TN, Middleton E Jr and Ogra PL:
Antiviral effect of flavonoids on human viruses. J Med Virol.
15:71–79. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kayser O, Kiderlen AF and Croft SL:
Natural products as anti-parasitic drugs. Parasitol Res. 90(Suppl
2): S55–S62. 2003. View Article : Google Scholar
|
|
10
|
Lin YS, Tsai PH, Kandaswami CC, Cheng CH,
Ke FC, Lee PP, Hwang JJ and Lee MT: Effects of dietary flavonoids,
luteolin, and quercetin on the reversal of epithelial-mesenchymal
transition in A431 epidermal cancer cells. Cancer Sci.
102:1829–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
López-Lázaro M: Flavonoids as anticancer
agents: Structure-activity relationship study. Curr Med Chem
Anticancer Agents. 2:691–714. 2002. View Article : Google Scholar
|
|
12
|
Chahar MK, Sharma N, Dobhal MP and Joshi
YC: Flavonoids: A versatile source of anticancer drugs. Pharmacogn
Rev. 5:1–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawaii S, Tomono Y, Katase E, Ogawa K and
Yano M: Antiproliferative activity of flavonoids on several cancer
cell lines. Biosci Biotechnol Biochem. 63:896–899. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh RP and Agarwal R: Natural flavonoids
targeting deregulated cell cycle progression in cancer cells. Curr
Drug Targets. 7:345–354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramos S: Effects of dietary flavonoids on
apoptotic pathways related to cancer chemoprevention. J Nutr
Biochem. 18:427–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pandurangan AK, Kumar SA, Dharmalingam P
and Ganapasam S: Luteolin, a bioflavonoid inhibits
azoxymethane-induced colon carcinogenesis: Involvement of iNOS and
COX-2. Pharmacogn Mag. 10(Suppl 2): S306–S310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tofighi Z, Molazem M, Doostdar B, Taban P,
Shahverdi AR, Samadi N and Yassa N: Antimicrobial activities of
three medicinal plants and investigation of flavonoids of
tripleurospermum disciforme. Iran J Pharm Res. 14:225–231.
2015.PubMed/NCBI
|
|
18
|
Li YC, Hung CF, Yeh FT, Lin JP and Chung
JG: Luteolin-inhibited
arylamineN-acetyltransferaseactivityandDNA-2-aminofluorene adduct
in human and mouse leukemia cells. Food Chem Toxicol. 39:641–647.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérez-García F, Adzet T and Cañigueral S:
Activity of artichoke leaf extract on reactive oxygen species in
human leukocytes. Free Radic Res. 33:661–665. 2000. View Article : Google Scholar
|
|
20
|
Gebhardt R: Inhibition of cholesterol
biosynthesis in HepG2 cells by artichoke extracts is reinforced by
glucosidase pretreatment. Phytother Res. 16:368–372. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang TT, Wang SK, Huang GL and Sun GJ:
Luteolin induced-growth inhibition and apoptosis of human
esophageal squamous carcinoma cell line Eca109 cells in vitro.
Asian Pac J Cancer Prev. 13:5455–5461. 2012. View Article : Google Scholar
|
|
22
|
Cai X, Lu W, Ye T, Lu M, Wang J, Huo J,
Qian S, Wang X and Cao P: The molecular mechanism of
luteolin-induced apoptosis is potentially related to inhibition of
angiogenesis in human pancreatic carcinoma cells. Oncol Rep.
28:1353–1361. 2012.PubMed/NCBI
|
|
23
|
Lu J, Li G, He K, Jiang W, Xu C, Li Z,
Wang H, Wang W, Wang H, Teng X, et al: Luteolin exerts a marked
antitumor effect in cMet-overexpressing patient-derived tumor
xenograft models of gastric cancer. J Transl Med. 13:422015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiu FL and Lin JK: Downregulation of
androgen receptor expression by luteolin causes inhibition of cell
proliferation and induction of apoptosis in human prostate cancer
cells and xenografts. Prostate. 68:61–71. 2008. View Article : Google Scholar
|
|
25
|
Chowdhury AR, Sharma S, Mandal S, Goswami
A, Mukhopadhyay S and Majumder HK: Luteolin, an emerging
anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.
Biochem J. 366:653–661. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Buening MK, Chang RL, Huang MT, Fortner
JG, Wood AW and Conney AH: Activation and inhibition of
benzo(a)pyrene and aflatoxin B1 metabolism in human liver
microsomes by naturally occurring flavonoids. Cancer Res. 41:67–72.
1981.PubMed/NCBI
|
|
27
|
Ferriola PC, Cody V and Middleton E Jr:
Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms
and structure-activity relationships. Biochem Pharmacol.
38:1617–1624. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ko WG, Kang TH, Lee SJ, Kim YC and Lee BH:
Effects of luteolin on the inhibition of proliferation and
induction of apoptosis in human myeloid leukaemia cells. Phytother
Res. 16:295–298. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Selvendiran K, Koga H, Ueno T, Yoshida T,
Maeyama M, Torimura T, Yano H, Kojiro M and Sata M: Luteolin
promotes degradation in signal transducer and activator of
transcription 3 in human hepatoma cells: An implication for the
antitumor potential of flavonoids. Cancer Res. 66:4826–4834. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L and
Lin C: Increase of Bax/ Bcl-XL ratio and arrest of cell cycle by
luteolin in immortalized human hepatoma cell line. Life Sci.
76:1883–1893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villanueva A, García C, Paules AB, Vicente
M, Megías M, Reyes G, de Villalonga P, Agell N, Lluís F, Bachs O,
et al: Disruption of the antiproliferative TGF-beta signaling
pathways in human pancreatic cancer cells. Oncogene. 17:1969–1978.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yee SB, Lee JH, Chung HY, Im KS, Bae SJ,
Choi JS and Kim ND: Inhibitory effects of luteolin isolated from
Ixeris sonchifolia Hance on the proliferation of HepG2 human
hepatocellular carcinoma cells. Arch Pharm Res. 26:151–156. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Derynck R, Jarrett JA, Chen EY, Eaton DH,
Bell JR, Assoian RK, Roberts AB, Sporn MB and Goeddel DV: Human
transforming growth factor-beta complementary DNA sequence and
expression in normal and transformed cells. Nature. 316:701–705.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Polyak K, Kato JY, Solomon MJ, Sherr CJ,
Massague J, Roberts JM and Koff A: p27Kip1, a cyclin-Cdk
inhibitor, links transforming growth factor-beta and contact
inhibition to cell cycle arrest. Genes Dev. 8:9–22. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toyoshima H and Hunter T: p27, a novel
inhibitor of G1 cyclin-Cdk protein kinase activity, is related to
p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Massagué J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim SG, Jong HS, Kim TY, Lee JW, Kim NK,
Hong SH and Bang YJ: Transforming growth factor-beta 1 induces
apoptosis through Fas ligand-independent activation of the Fas
death pathway in human gastric SNU-620 carcinoma cells. Mol Biol
Cell. 15:420–434. 2004. View Article : Google Scholar :
|
|
39
|
Depoortere F, Pirson I, Bartek J, Dumont
JE and Roger PP: Transforming growth factor beta(1) selectively
inhibits the cyclic AMP-dependent proliferation of primary thyroid
epithelial cells by preventing the association of cyclin D3-cdk4
with nuclear p27(kip1). Mol Biol Cell. 11:1061–1076. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park BJ, Park JI, Byun DS, Park JH and Chi
SG: Mitogenic conversion of transforming growth factor-beta1 effect
by oncogenic Ha-Ras-induced activation of the mitogen-activated
protein kinase signaling pathway in human prostate cancer. Cancer
Res. 60:3031–3038. 2000.PubMed/NCBI
|
|
41
|
Nakao A, Imamura T, Souchelnytskyi S,
Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH,
Miyazono K, et al: TGF-beta receptor-mediated signalling through
Smad2, Smad3 and Smad4. EMBO J. 16:5353–5362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Q, Zhao XH and Wang ZJ: Cytotoxicity
of flavones and flavonols to a human esophageal squamous cell
carcinoma cell line (KYSE-510) by induction of G2/M arrest and
apoptosis. Toxicol In Vitro. 23:797–807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kobayashi T, Nakata T and Kuzumaki T:
Effect of flavonoids on cell cycle progression in prostate cancer
cells. Cancer Lett. 176:17–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Walker A, Taylor ST, Hickman JA and Dive
C: Germinal center-derived signals act with Bcl-2 to decrease
apoptosis and increase clonogenicity of drug-treated human B
lymphoma cells. Cancer Res. 57:1939–1945. 1997.PubMed/NCBI
|
|
45
|
Cory S, Vaux DL, Strasser A, Harris AW and
Adams JM: Insights from Bcl-2 and Myc: Malignancy involves
abrogation of apoptosis as well as sustained proliferation. Cancer
Res. 59(Suppl): S1685–S1692. 1999.
|
|
46
|
Green DR and Evan GI: A matter of life and
death. Cancer Cell. 1:19–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Crescenzi E and Palumbo G: Bcl-2 exerts a
pRb-mediated cell cycle inhibitory function in HEC1B endometrial
carcinoma cells. Gynecol Oncol. 81:184–192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Attoub S, Hassan AH, Vanhoecke B, Iratni
R, Takahashi T, Gaben AM, Bracke M, Awad S, John A, Kamalboor HA,
et al: Inhibition of cell survival, invasion, tumor growth and
histone deacetylase activity by the dietary flavonoid luteolin in
human epithelioid cancer cells. Eur J Pharmacol. 651:18–25. 2011.
View Article : Google Scholar
|
